
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 16 |
| Chemical drugs | 3 |
| Molecular glue | 1 |
Target |
Mechanism 5-HT6 receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FLT3 modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDE4 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Oct 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date12 May 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Pyrroloisoquinoline derivatives(Palacký University) ( DNA ) | Diabetes Mellitus More | Preclinical |
3-aryl-3-azetidinyl acetic acid methyl ester derivatives (Vipergen/Palacky University Olomouc) | Alzheimer Disease More | Preclinical |
VFP-B-3 ( PDE4 x PDE7 ) | Autoimmune Diseases More | Preclinical |
PZ-1727 ( 5-HT6 receptor ) | Neurodegenerative Diseases More | Preclinical |
NBD-14204 ( ITIH4 ) | Acute Myeloid Leukemia More | Preclinical |





